drugset / Trial / NCT01142219
L-Arginine and Sickle Cell Disease
Phase 3
Completed
40 enrolled
Hospital de Clinicas de Porto Alegre
Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine) · collabAssociação de Amigos da Hematologia (HEMOAMIGOS) · collabFundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
One of the main problems in sickle cell disease is the decreased bioavailability of nitric oxide and arginine. This study was designed to assess if treating sickle cell disease patients with L-arginine would improve pulmonary arterial pressure and other aspects.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-01
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-arginine | Small molecule | 0.1 g/kg | Oral |